Israel approves Y-mabs cancer drug
![Photo: Arne Immanuel B'nsch/AP/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14358556.ece/ALTERNATES/schema-16_9/18311618660504-1920x1079we.jpg)
A collaboration between Takeda and Y-mabs on the commercialization of the latter’s two products, Danyelza (naxitamab) and omburtamab in Israel, is moving into a new phase.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Y-mabs reports second quarter sales increase for cancer drug
For subscribers
Takeda's profit shrank in Q1
For subscribers
Former CEO left Y-mabs with USD 10.7m in severance pay
For subscribers